BioCryst Pharmaceuticals, Inc. Securities Litigation
On or around 07/20/2018 (Notice of voluntarily dismissal)
Filing Date: March 06, 2018
BioCryst Pharmaceuticals, Inc. ("BCRX") designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases.
According to the Complaint, on January 21, 2018, the merger agreement and the voting and support agreements were executed by Idera Pharmaceuticals, Inc. ("IDRA") and BCRX. The transaction was announced by joint press release on the morning of January 22, 2018.
On February 27, 2018, Defendants filed a Form S-4 Registration Statement (the “Registration Statement”) with the United States Securities and Exchange Commission in connection with the Proposed Mergers. The Complaint alleges that the Registration Statement fails to provide material information regarding the Proposed Mergers.
This case was voluntarily dismissed on July 20, 2018.
Company & Securities Information
Defendant: BioCryst Pharmaceuticals, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: BCRX
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Melvyn Klein, et al. v. BioCryst Pharmaceuticals, Inc., et al.
COURT: D. Delaware
DOCKET #: 18-CV-00358
JUDGE: Hon. Leonard P. Stark
DATE FILED: 03/06/2018
CLASS PERIOD START: 01/22/2018
CLASS PERIOD END: 03/06/2018
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Gainey McKenna & Egleston 440 Park Avenue South, 5th Floor, Gainey McKenna & Egleston, NY 10016 212.983.1300 212.983.0380 ·
O'Kelly Ernst & Joyce, LLC 901 N. Market Street, Suite 1000, O'Kelly Ernst & Joyce, LLC, DE ·
First Identified Complaint (FIC) Filings:
U.S. District Court Civil Docket
Notice of Voluntary Dismissal
—Reference Complaint Complaint Related Data is not available
Related District Court Filings
—Related District Court Filings Data is not available